Khan Khalid M, Iqtadar Somia, Nasir Mahmood, Siddiqui Anum S, Rehman Atiq
Internal Medicine: Gastroenterology, Jinnah Hospital, Lahore, PAK.
Internal Medicine, King Edward Medical University & Mayo Hospital, Lahore, PAK.
Cureus. 2020 May 17;12(5):e8174. doi: 10.7759/cureus.8174.
Hypertension is a significant public health problem and one of the major noncommunicable diseases at the endemic level in Pakistan. This study was done to determine the efficacy of amlodipine/valsartan (Aml/Val) once-daily dose in reducing blood pressure (BP) after eight weeks of therapy.
This study is an open-labeled observational study carried out for a period of 12 months. Some 769 participants of either gender between the ages of 18 and 70 years selected after taking written informed consent had a BP of >139/89 mmHg (not controlled) on monotherapy with a minimum 30 days of treatment. Therapy to control their high BP was initiated with Aml/Val (Avsar, PharmEvo Pvt Ltd, Karachi, Pakistan) at the time of their enrolment in the study. Pregnant females and patients with secondary hypertension were excluded. Data were analyzed using SPSS version 20.0 and chi-square test was used for inferential analysis. p-values less than 0.05 were considered significant.
At the end of week one, less than half of the patients achieved the desired level of BP while the majority achieved this level by the end of the study. Some 75.6% patients achieved targeted BP with Aml/Val 80/5 mg tablet, 18.5% achieved targeted BP with Aml/Val 160/5 mg tablet, and 5.9% achieved the targeted BP with Aml/Val 160/10 mg tablet at the end of the eighth week. The compliance rate was 99.2% at the first week, 98.9% at the fourth week, and 99.9% at the eighth week of treatment.
Our study concluded that Aml/Val (Avsar) combination therapy was very effective in controlling BP among patients who were uncontrolled with other monotherapies for at least one month.
高血压是一个重大的公共卫生问题，也是巴基斯坦地方性流行的主要非传染性疾病之一。本研究旨在确定氨氯地平/缬沙坦（Aml/Val）每日一次给药方案在治疗八周后降低血压（BP）的疗效。
本研究是一项为期12个月的开放标签观察性研究。在获得书面知情同意后，选取了769名年龄在18至70岁之间的男女参与者，他们在接受至少30天单药治疗后血压>139/89 mmHg（未得到控制）。在他们入组研究时，开始使用Aml/Val（Avsar，巴基斯坦卡拉奇PharmEvo Pvt Ltd公司生产）进行控制高血压的治疗。排除怀孕女性和继发性高血压患者。使用SPSS 20.0版进行数据分析，并使用卡方检验进行推断性分析。p值小于0.05被认为具有统计学意义。
在第一周结束时，不到一半的患者达到了理想的血压水平，而大多数患者在研究结束时达到了该水平。在第八周结束时，约75.6%的患者使用氨氯地平/缬沙坦80/5毫克片剂达到了目标血压，18.5%的患者使用氨氯地平/缬沙坦160/5毫克片剂达到了目标血压，5.9%的患者使用氨氯地平/缬沙坦160/10毫克片剂达到了目标血压。治疗第一周的依从率为99.2%，第四周为98.9%，第八周为99.9%。
我们的研究得出结论，对于至少一个月使用其他单药治疗未得到控制的患者，氨氯地平/缬沙坦（Avsar）联合治疗在控制血压方面非常有效。
